Silva Carlos F M, Leão Teresa, Dias Filipa, Tomás Ana M, Pinto Diana C G A, Oliveira Eduardo F T, Oliveira Ana, Fernandes Pedro A, Silva Artur M S
LAQV-REQUIMTE, Department of Chemistry, University of Aveiro, 3810-193 Aveiro, Portugal.
i3S, Instituto de Investigação e Inovação em Saúde, 4200-135 Porto, Portugal.
Pharmaceutics. 2023 Feb 16;15(2):669. doi: 10.3390/pharmaceutics15020669.
Leishmaniasis is one of the most neglected diseases in modern times, mainly affecting people from developing countries of the tropics, subtropics and the Mediterranean basin, with approximately 350 million people considered at risk of developing this disease. The incidence of human leishmaniasis has increased over the past decades due to failing prevention and therapeutic measures-there are no vaccines and chemotherapy, which is problematic. Acridine derivatives constitute an interesting group of nitrogen-containing heterocyclic compounds associated with numerous bioactivities, with emphasis to their antileishmanial potential. The present work builds on computational studies focusing on a specific enzyme of the parasite, -adenosylmethionine decarboxylase (AdoMet DC), with several 1,2,3,4-tetrahydro-acridines emerging as potential inhibitors, evidencing this scaffold as a promising building block for novel antileishmanial pharmaceuticals. Thus, several 1,2,3,4-tetrahydroacridine derivatives have been synthesized, their activity against promastigotes evaluated and a structure-activity relationship (SAR) study was developed based on the results obtained. Even though the majority of the 1,2,3,4-tetrahydroacridines evaluated presented high levels of toxicity, the structural information gathered in this work allowed its application with another scaffold (quinoline), leading to the obtention of ,-bis(7-chloroquinolin-4-yl)dodecane-1,12-diamine () as a promising novel antileishmanial agent (IC = 0.60 ± 0.11 μM, EC = 11.69 ± 3.96 μM and TI = 19.48).
利什曼病是现代最被忽视的疾病之一,主要影响热带、亚热带和地中海盆地发展中国家的人群,约有3.5亿人被认为有感染这种疾病的风险。由于预防和治疗措施不力,过去几十年来人类利什曼病的发病率有所上升——目前尚无疫苗和化疗药物,这是个问题。吖啶衍生物是一类有趣的含氮杂环化合物,具有多种生物活性,尤其具有抗利什曼原虫的潜力。目前的工作基于对寄生虫的一种特定酶——腺苷甲硫氨酸脱羧酶(AdoMet DC)的计算研究,几种1,2,3,4 - 四氢吖啶成为潜在抑制剂,证明该骨架是新型抗利什曼病药物的有前景的构建模块。因此,合成了几种1,2,3,4 - 四氢吖啶衍生物,评估了它们对前鞭毛体的活性,并根据所得结果开展了构效关系(SAR)研究。尽管所评估的大多数1,2,3,4 - 四氢吖啶具有高毒性水平,但这项工作中收集的结构信息使其能够与另一种骨架(喹啉)一起应用,从而获得了作为一种有前景的新型抗利什曼病药物的1,12 - 二氨基 - 双(7 - 氯喹啉 - 4 - 基)十二烷(IC = 0.60 ± 0.11 μM,EC = 11.69 ± 3.96 μM,TI = 19.48)。